Dr. Reddys Laboratories Ltd 2021 AR2
The report outlines Dr. Reddy's Laboratories Limited's operational and financial performance for the fiscal year 2020-2021, highlighting its proactive response to the COVID-19 pandemic. The company expanded its therapeutic portfolio by launching Remdesivir, Avigan, and the Sputnik V vaccine in India, while prioritizing employee safety and community support. Financially, consolidated revenues grew by 9% to ₹189.7 billion, driven by strong generic sales in Europe and emerging markets. Additionally, the company advanced its environmental commitment by joining the Science Based Targets initiative (SBTi) to reduce carbon emissions by 55% by 2030.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2021
Type: AR2
Pages: 143
Back to company
Dr. Reddys Laboratories Ltd
Annual Report
The report outlines Dr. Reddy's Laboratories Limited's operational and financial performance for the fiscal year 2020-2021, highlighting its proactive response to the COVID-19 pandemic. The company expanded its therapeutic portfolio by launching Remdesivir, Avigan, and the Sputnik V vaccine in India, while prioritizing employee safety and community support. Financially, consolidated revenues grew by 9% to ₹189.7 billion, driven by strong generic sales in Europe and emerging markets. Additionally, the company advanced its environmental commitment by joining the Science Based Targets initiative (SBTi) to reduce carbon emissions by 55% by 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees